Healthcare / BiotechnologyShanghai
$18.81
-0.58 (-2.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-23.4M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.7B
P/E
47.0x
↑EV/EBITDA
28.8x
↑ROE
6.4%
↑Gross Margin
64.1%
↑Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+15.4%
FCF CAGR
—
FCF margin
15.4%
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $793.4M · net income $142.6M · FCF $122.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $793.4M | $793.4M | $686.8M | $622.2M | $516.5M |
| Net Income | $142.6M | $142.6M | $109.8M | $158.9M | $164.7M |
| EBITDA | $259.2M | $259.2M | $208.4M | $217.8M | $213.2M |
| EPS | 0.35 | 0.35 | 0.27 | 0.39 | 0.42 |
| Gross Margin | 64.1% | 64.1% | 62.0% | 67.6% | 71.4% |
| Operating Margin | 22.9% | 22.9% | 17.8% | 26.7% | 33.2% |
| Net Margin | 18.0% | 18.0% | 16.0% | 25.5% | 31.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.06 | 0.06 | 0.01 |
| Current Ratio | 3.58 | 3.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $122.0M | $122.0M | $-23.4M | $-89.3M | $-84.3M |
| Returns | |||||
| ROE | 6.4% | 6.4% | 5.1% | 7.5% | 8.3% |
| Valuation | |||||
| P/E | 47.02 | 47.02 | 45.33 | 47.95 | 65.00 |
| EV/EBITDA | 28.82 | 28.82 | 21.16 | 32.97 | 48.30 |
| P/B | 3.44 | 3.44 | 2.33 | 3.59 | 5.41 |
| Growth & Yield | |||||
| Revenue Growth | 15.5% | 15.5% | 10.4% | 20.5% | — |
| EPS Growth | 29.6% | 29.6% | -30.8% | -7.1% | — |
| Dividend Yield | 0.7% | 0.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
68.3%
EPS terminal req.
$1.67
Spread vs growth
-38.7%
5Y implied EPS CAGR
42.0%
EPS terminal req.
$2.02
Spread vs growth
-12.4%
10Y implied EPS CAGR
25.0%
EPS terminal req.
$3.25
Spread vs growth
4.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+58.4%
Start / end P/E
44.2x → 53.7x
EPS bridge
0.27 → 0.35
Residual
+6.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.